ECSP21033637A - Methods and Compositions for Editing RNAs - Google Patents

Methods and Compositions for Editing RNAs

Info

Publication number
ECSP21033637A
ECSP21033637A ECSENADI202133637A ECDI202133637A ECSP21033637A EC SP21033637 A ECSP21033637 A EC SP21033637A EC SENADI202133637 A ECSENADI202133637 A EC SENADI202133637A EC DI202133637 A ECDI202133637 A EC DI202133637A EC SP21033637 A ECSP21033637 A EC SP21033637A
Authority
EC
Ecuador
Prior art keywords
rna
methods
compositions
editing
present application
Prior art date
Application number
ECSENADI202133637A
Other languages
English (en)
Inventor
Wensheng Wei
Chunhui Wang
Liang Qu
Zhuo Zhou
Zhongzheng Cao
Zongyi Yi
Shiyou Zhu
Pengfei Yuan
Original Assignee
Univ Beijing
Edigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70163607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21033637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Beijing, Edigene Inc filed Critical Univ Beijing
Publication of ECSP21033637A publication Critical patent/ECSP21033637A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

La presente solicitud proporciona métodos para editar ARN mediante la introducción de un ARN de reclutamiento de desaminasas en una célula hospedera para la desaminación de una adenosina en un ARN objetivo; la presente solicitud proporciona además ARN de reclutamiento de desaminasas usados en los métodos de edición de ARN y composiciones que los comprenden.
ECSENADI202133637A 2018-10-12 2021-05-12 Methods and Compositions for Editing RNAs ECSP21033637A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110105 2018-10-12
CN2019082713 2019-04-15
PCT/CN2019/110782 WO2020074001A1 (en) 2018-10-12 2019-10-12 Methods and Compositions for Editing RNAs

Publications (1)

Publication Number Publication Date
ECSP21033637A true ECSP21033637A (es) 2021-08-31

Family

ID=70163607

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202133637A ECSP21033637A (es) 2018-10-12 2021-05-12 Methods and Compositions for Editing RNAs

Country Status (21)

Country Link
US (2) US20210355494A1 (es)
EP (3) EP4527931A1 (es)
JP (2) JP7252328B2 (es)
KR (1) KR102666695B1 (es)
CN (4) CN116218836A (es)
AU (2) AU2019357450B2 (es)
BR (1) BR112021006844A8 (es)
CA (1) CA3115864A1 (es)
CL (1) CL2021000880A1 (es)
CO (1) CO2021005956A2 (es)
CR (1) CR20210243A (es)
DK (1) DK3864152T5 (es)
EC (1) ECSP21033637A (es)
ES (1) ES2962434T3 (es)
IL (1) IL282191A (es)
MX (1) MX2021004187A (es)
PE (1) PE20211402A1 (es)
PH (1) PH12021550805A1 (es)
SG (1) SG11202103666PA (es)
TW (1) TW202028466A (es)
WO (1) WO2020074001A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612353A (zh) 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
PE20211402A1 (es) * 2018-10-12 2021-08-02 Univ Beijing Metodos y composiciones para editar acidos ribonucleicos
CN113573717A (zh) 2019-01-22 2021-10-29 科罗生物公司 Rna编辑的寡核苷酸及其用途
CA3127241A1 (en) 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2020210900B2 (en) 2019-01-22 2025-04-24 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof
CA3136735A1 (en) 2019-04-15 2020-10-22 Edigene Inc. Methods and compositions for editing rnas
AU2020313143B2 (en) 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
AU2020418228A1 (en) 2019-12-30 2022-08-18 Edigene Therapeutics (Beijing) Inc. Leaper technology based method for treating MPS IH and composition
AU2020418026A1 (en) 2019-12-30 2022-08-18 Edigene Therapeutics (Beijing) Inc. Method for treating usher syndrome and composition thereof
PE20230703A1 (es) * 2020-04-15 2023-04-24 Edigene Therapeutics Beijing Inc Metodo y farmaco para tratar el sindrome de hurler
CA3173012A1 (en) * 2020-04-22 2021-10-28 Susan BYRNE Compositions and methods using snrna components
WO2021243023A1 (en) * 2020-05-28 2021-12-02 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of serpina1
CN113897359A (zh) * 2020-07-06 2022-01-07 博雅辑因（北京）生物科技有限公司 一种改善的rna编辑方法
KR20230035362A (ko) * 2020-07-06 2023-03-13 에디진 테라퓨틱스 (베이징) 인크. 개선된 rna 편집 방법
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for editing RNA and a method for using them
EP4240338A4 (en) * 2021-01-04 2025-08-06 Univ California IN VIVO PROGRAMMABLE RNA EDITING BY RECRUITMENT OF ENDOGENOUS ADARS
JP2024504608A (ja) * 2021-01-12 2024-02-01 北京大学 遺伝子操作ｒｎａを使用した内因性ａｄａｒの活用による標的化ｒｎａの編集
KR20240021893A (ko) * 2021-06-15 2024-02-19 메사추세츠 인스티튜트 오브 테크놀로지 데아미나제 기반 rna 센서
US20240279656A1 (en) * 2021-06-29 2024-08-22 Shape Therapeutics Inc. Engineered Guide RNAs and Polynucleotides
TW202321451A (zh) * 2021-08-18 2023-06-01 北京大學 工程化的 adar 招募 rnas 及其使用方法
US20250102522A1 (en) 2021-10-07 2025-03-27 Hepatx Corporation Methods of tracking donor cells in a recipient
EP4423266A1 (en) * 2021-10-27 2024-09-04 Shape Therapeutics Inc. Engineered rnas
JP2024541983A (ja) * 2021-10-29 2024-11-13 デューク ユニバーシティ Ｒｎａプログラム可能な細胞編集のための組成物およびシステム、ならびにそれを作製および使用する方法
WO2023143539A1 (en) * 2022-01-28 2023-08-03 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use thereof
WO2023185231A1 (en) * 2022-04-02 2023-10-05 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use for usher syndrome
WO2024228735A2 (en) * 2022-07-15 2024-11-07 Georgia Tech Research Corporation Anti-sars-cov-1 and anti-sars-cov-2 activatable rnase guide sequences
EP4605529A1 (en) * 2022-10-18 2025-08-27 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising programmable snrnas for rna editing
US12565665B2 (en) 2022-12-21 2026-03-03 Trustees Of Boston University Compositions and methods for controlled mRNA translation and stability
CN118620958A (zh) * 2023-03-08 2024-09-10 广州医科大学 一种抗原表位的制备方法
WO2024197951A1 (zh) * 2023-03-31 2024-10-03 时夕(广州)生物科技有限公司 一种与rna编辑靶位点形成编辑底物的序列
CN118853661A (zh) * 2023-04-28 2024-10-29 时夕(广州)生物科技有限公司 编辑rna的方法、组合物及其应用
WO2024235283A1 (en) * 2023-05-16 2024-11-21 Peking University Method of modulating rna splicing
EP4763979A1 (en) 2023-08-18 2026-06-24 EdiGene Biotechnology, Inc. Engineered t cell having prolonged in vivo half-life and preparation method therefor
WO2025206105A1 (ja) * 2024-03-29 2025-10-02 株式会社Frest 標的アデノシンに対する部位特異的編集を誘導するオリゴヌクレオチド
CN121059628A (zh) * 2024-06-03 2025-12-05 时夕(广州)生物科技有限公司 调控RNA剪接的向导agRNA
CN119505015B (zh) * 2024-11-15 2025-10-17 北京大学 一种融合蛋白及其应用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297830B1 (ko) * 2010-09-10 2013-08-19 한국생명공학연구원 신규한 ｒｎａ 결합 단백질 및 이를 이용한 무표지 마이크로 ｒｎａ 검출방법
CN107532162A (zh) 2014-12-12 2018-01-02 托德·M·伍尔夫 用于利用寡核苷酸编辑细胞中核酸的组合物和方法
AU2015367378A1 (en) * 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
WO2017010556A1 (ja) 2015-07-14 2017-01-19 学校法人福岡大学 部位特異的ｒｎａ変異導入方法およびそれに使用する標的編集ガイドｒｎａならびに標的ｒｎａ－標的編集ガイドｒｎａ複合体
US11396672B2 (en) * 2015-08-31 2022-07-26 The University Of Chicago Composition and methods for detecting adenosine modifications
DE102015012522B3 (de) * 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Verfahren und Substanzen zur gerichteten RNA-Editierung
EP3475424A1 (en) * 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
CN110612353A (zh) * 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
CN110959039B (zh) 2017-03-15 2025-03-14 博德研究所 新型cas13b直向同源物crispr酶和系统
KR102338449B1 (ko) * 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
PE20211402A1 (es) * 2018-10-12 2021-08-02 Univ Beijing Metodos y composiciones para editar acidos ribonucleicos

Also Published As

Publication number Publication date
CO2021005956A2 (es) 2021-07-30
KR20210076082A (ko) 2021-06-23
ES2962434T3 (es) 2024-03-19
EP3864152B1 (en) 2023-08-16
AU2019357450B2 (en) 2023-01-12
WO2020074001A1 (en) 2020-04-16
BR112021006844A8 (pt) 2023-03-21
PH12021550805A1 (en) 2021-10-04
CN115651927B (zh) 2023-06-16
JP7252328B2 (ja) 2023-04-04
CR20210243A (es) 2021-10-07
CN113631708A (zh) 2021-11-09
IL282191A (en) 2021-05-31
EP4527931A1 (en) 2025-03-26
US20210355494A1 (en) 2021-11-18
CA3115864A1 (en) 2020-04-16
US20210310026A1 (en) 2021-10-07
AU2023202184B2 (en) 2025-06-12
CN115651927A (zh) 2023-01-31
AU2019357450A1 (en) 2021-06-03
CN116218836A (zh) 2023-06-06
CL2021000880A1 (es) 2021-12-10
TW202028466A (zh) 2020-08-01
AU2023202184A1 (en) 2023-05-04
EP4306116A2 (en) 2024-01-17
EP4306116A3 (en) 2024-04-17
CN116042611A (zh) 2023-05-02
MX2021004187A (es) 2021-09-08
CN113631708B (zh) 2022-05-24
KR102666695B1 (ko) 2024-05-23
EP3864152A1 (en) 2021-08-18
PE20211402A1 (es) 2021-08-02
DK3864152T3 (da) 2023-10-09
EP3864152A4 (en) 2021-10-13
JP2021534810A (ja) 2021-12-16
JP2023078373A (ja) 2023-06-06
DK3864152T5 (da) 2024-08-12
BR112021006844A2 (pt) 2021-07-20
SG11202103666PA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
ECSP21080618A (es) Methods and Compositions for Editing RNAs
CO2021005956A2 (es) Métodos y composiciones para editar ácidos ribonucleicos
CO2022001359A2 (es) Edición de ácido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actúa sobre ácido ribonucleico endógeno (adar) utilizando ácidos ribonucleicos (arn) modificados genéticamente
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
BR112018069417A2 (pt) método para fornecer rna fita simples e ssrna
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
MX2017010746A (es) Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas.
MX2016004575A (es) Metodos de modificacion de celulas huespedes.
MX2012013037A (es) Composiciones de endorribonucleasa y metodos de uso de las mismas.
BR102016018569A2 (pt) sistemas e métodos de retentor para eletrodo de soldagem com bastão
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
BR112019007365A2 (pt) métodos e composições para imunoterapia com tusc2
MX2020010360A (es) Sistemas, metodos y composicion de uso de mutantes de rnasa iii para producir sarn para controlar infeccion por patogeno huesped.
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
MX2020010966A (es) Formulaciones de aditivos de poliolefina.
CL2021001708A1 (es) Métodos para formar poliplejos
EA202191004A1 (ru) Способы и композиции для редактирования рнк
MX2021013525A (es) Metodos y composiciones que usan celulas regulables auxotroficas.
AR106259A1 (es) Métodos de preservar la actividad biológica de los ácidos ribonucleicos
AR110675A1 (es) Oligonucleótidos modificados y métodos de uso
BR112018015626A2 (pt) sistema fúngico de produção de alto nível de proteínas